Philips Accelerates the Development of Magnetic Particle Imaging Technology

PhilipsRoyal Philips Electronics (NYSE: PHG, AEX: PHI) has initiated a German public-private partnership that aims to advance the development of whole-body Magnetic Particle Imaging (MPI) systems and preclinical hybrid systems that combine MPI with Magnetic Resonance Imaging (MRI). The German Federal Ministry of Education and Research has made a commitment to provide EUR 10.6 million funding to the consortium partners. The target size of the consortium budget, comprising contributions from the German government and the consortium's public/private partners, is EUR 20.3 million.

Philips is committed to delivering leading-edge imaging solutions to help in the early detection, diagnosis and treatment of disease. Researching future-generation imaging technologies such as MPI underpins the long-term nature of this commitment. MPI was invented by scientists at Philips. It relies on the magnetic properties of iron-oxide nanoparticles (the so-called tracer) that are injected into the bloodstream. An MPI system spatially and quantitatively detects these iron-oxide nanoparticles in order to produce three-dimensional images of physiological processes. The technology has already proved capable of capturing accurate real-time 3D-images of blood flow and heart motion in mice.

"As part of our Open Innovation approach, Philips has initiated the Magnetic Particle Imaging Technology - MAPIT - consortium to accelerate the translation of this innovative new imaging concept into clinical practice," says Michael Kuhn, Vice President Technology Strategy at Philips Healthcare. "Realizing the full potential of MPI to help in elucidating the processes associated with disease requires an integrated approach and a collaborative effort. I am convinced that the multidisciplinary MAPIT consortium is well positioned to advance MPI development in the areas of instrumentation, tracers, and application research."

"Constant improvements in medical imaging technology have significantly boosted advances in healthcare. Based on the level of performance that has been demonstrated in preclinical studies, I consider MPI to be a new imaging modality with the real potential to improve diagnostic imaging in cardiology and oncology, as well as being a tremendous tool for the advancement of molecular imaging in general," says Professor Bernd Hamm, Director of the Department of Radiology and Chair of Radiology at the Charité - Universitätsmedizin Berlin.

Philips and the University of Lübeck, two of the three proposed consortium partners in the instrumentation area, will focus on the development of whole-body MPI demonstrators. The third instrumentation partner, Bruker Corporation (NASDAQ: BRKR), will focus on developing a simultaneous or consecutive preclinical MPI plus MRI capability. This will complement the functional MPI information with morphological information from MRI for the purposes of preclinical imaging. In the area of tracer development, the proposed partners Bayer Schering Pharma AG, Miltenyi Biotec, Charité-Universitätsmedizin Berlin and the Physikalisch-Technische Bundesanstalt (PTB) aim to develop magnetic nanoparticle materials optimized for MPI.

Two principal application areas will be explored by the consortium: functional cardiovascular measurements (such as myocardial perfusion) and image-guidance of cardiovascular interventions (using interventional devices optimized for MPI guidance).

The results achieved at the Philips Research Laboratories in Hamburg (Germany) in the preceding MAGIC (Magnetic Particle Imaging for Cardiovascular Applications) research consortium contributed significantly to the development of MPI. The MAGIC project, which was also funded by the German Federal Ministry of Education and Research, has already resulted in an agreement between Philips and Bruker Biospin regarding the commercialization of MPI scanners for the preclinical market.

Related news articles:

About Royal Philips Electronics
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a diversified health and well-being company, focused on improving people’s lives through timely innovations. As a world leader in healthcare, lifestyle and lighting, Philips integrates technologies and design into people-centric solutions, based on fundamental customer insights and the brand promise of "sense and simplicity". Headquartered in the Netherlands, Philips employs more than 118,000 employees in more than 60 countries worldwide. With sales of US 32.3 billion in 2009, the company is a market leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well-being and pleasure with strong leadership positions in flat TV, male shaving and grooming, portable entertainment and oral healthcare.

Most Popular Now

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...

AI-Driven Smart Devices to Transform Hea…

AI-powered, internet-connected medical devices have the potential to revolutionise healthcare by enabling early disease detection, real-time patient monitoring, and personalised treatments, a new study suggests. They are already saving lives...